Terms: = Prostate cancer AND CDH1, uvomorulin, 999, P12830, ENSG00000039068, CDHE, Arc-1, UVO, LCAM, CD324, ECAD AND Treatment
71 results:
1. Comparative Study of Different Imaging Modalities for Diagnosis of Bone Metastases of prostate cancer: A Bayesian Network Meta-analysis.
Kim K; Ha M; Kim SJ
Clin Nucl Med; 2024 Apr; 49(4):312-318. PubMed ID: 38350066
[TBL] [Abstract] [Full Text] [Related]
2. Phenotypic Characterization of 2D and 3D prostate cancer Cell Systems Using Electrical Impedance Spectroscopy.
Crowell LL; Yakisich JS; Aufderheide B; Adams TNG
Biosensors (Basel); 2023 Dec; 13(12):. PubMed ID: 38131796
[TBL] [Abstract] [Full Text] [Related]
3. prostate cancer Disparities in Metastatic and treatment Status for Hispanic Americans Based on Country of Origin Compared to Non-Hispanic Whites Using the National cancer Database.
Estrada-Mendizabal RJ; Dhaliwal AS; Bertolo AJ; Batai K; Heimark R; Recio-Boiles A; Chipollini J
Clin Genitourin Cancer; 2024 Feb; 22(1):e148-e155.e1. PubMed ID: 37903669
[TBL] [Abstract] [Full Text] [Related]
4. Aridanin and oleanane-3- O-β-D-glucoside-2'-acetamide obtained from Tetrapleura tetraptera (Schumach. & Thonn) Taub. (Fabaceae) induces potent apoptotic activity in human prostate cancer cells.
Kamdem MHK; Zingue S; Grein T; Maxeiner S; Rutz J; Mmutlane EM; Njamen D; Blaheta RA; Ndinteh DT
J Ethnopharmacol; 2024 Jan; 319(Pt 3):117298. PubMed ID: 37866463
[TBL] [Abstract] [Full Text] [Related]
5. Effects of exercise training on cancer patients undergoing neoadjuvant treatment: A systematic review.
Malveiro C; Correia IR; Cargaleiro C; Magalhães JP; de Matos LV; Hilário S; Sardinha LB; Cardoso MJ
J Sci Med Sport; 2023 Nov; 26(11):586-592. PubMed ID: 37696693
[TBL] [Abstract] [Full Text] [Related]
6. Rosiglitazone has a null association with the risk of prostate cancer in type 2 diabetes patients.
Tseng CH
Front Endocrinol (Lausanne); 2023; 14():1185053. PubMed ID: 37560306
[TBL] [Abstract] [Full Text] [Related]
7. A pilot study of an organised population-based testing programme for prostate cancer.
Alterbeck M; Thimansson E; Bengtsson J; Baubeta E; Zackrisson S; Bolejko A; Sandeman K; Carlsson S; Jiborn T; Bjartell A
BJU Int; 2024 Jan; 133(1):87-95. PubMed ID: 37523331
[TBL] [Abstract] [Full Text] [Related]
8. Contemporary patterns of local ablative therapies for prostate cancer at United States cancer centers: results from a national registry.
Koelker M; Labban M; Frego N; Meyer CP; Salomon G; Lipsitz SR; Withington J; Moore CM; Tempany CM; Tuncali K; George A; Kibel AS; Trinh QD; Cole AP
World J Urol; 2023 May; 41(5):1309-1315. PubMed ID: 36930254
[TBL] [Abstract] [Full Text] [Related]
9. Anticancer activities of Brachydin C in human prostate tumor cells (DU145) grown in 2D and 3D models: Stimulation of cell death and downregulation of metalloproteinases in spheroids.
Oliveira LCB; Ribeiro DL; Nascimento JRD; Rocha CQD; Cólus IMS; Serpeloni JM
Chem Biol Drug Des; 2022 Nov; 100(5):747-762. PubMed ID: 35775856
[TBL] [Abstract] [Full Text] [Related]
10. The added influence of genomics and post-MRI confirmatory biopsy results to MRI results alone on medical decision making for men with favorable risk prostate cancer being considered for active surveillance.
Wang M; Qi J; George AK; Semerjian A; Linsell SM; Montie JE; Cher ML; Ginsburg KB;
Prostate; 2022 Jun; 82(10):1068-1074. PubMed ID: 35468226
[TBL] [Abstract] [Full Text] [Related]
11. prostate volume prediction on MRI: tools, accuracy and variability.
Hamzaoui D; Montagne S; Granger B; Allera A; Ezziane M; Luzurier A; Quint R; Kalai M; Ayache N; Delingette H; Renard-Penna R
Eur Radiol; 2022 Jul; 32(7):4931-4941. PubMed ID: 35169895
[TBL] [Abstract] [Full Text] [Related]
12. Effects of Magnetic Resonance Imaging Targeting on Overdiagnosis and Overtreatment of prostate cancer.
Vickers AJ
Eur Urol; 2021 Nov; 80(5):567-572. PubMed ID: 34294510
[TBL] [Abstract] [Full Text] [Related]
13. Comparison of Multimodal Therapies and Outcomes Among Patients With High-Risk prostate cancer With Adverse Clinicopathologic Features.
Kishan AU; Karnes RJ; Romero T; Wong JK; Motterle G; Tosoian JJ; Trock BJ; Klein EA; Stish BJ; Dess RT; Spratt DE; Pilar A; Reddy C; Levin-Epstein R; Wedde TB; Lilleby WA; Fiano R; Merrick GS; Stock RG; Demanes DJ; Moran BJ; Braccioforte M; Huland H; Tran PT; Martin S; Martínez-Monge R; Krauss DJ; Abu-Isa EI; Alam R; Schwen Z; Chang AJ; Pisansky TM; Choo R; Song DY; Greco S; Deville C; McNutt T; DeWeese TL; Ross AE; Ciezki JP; Boutros PC; Nickols NG; Bhat P; Shabsovich D; Juarez JE; Chong N; Kupelian PA; D'Amico AV; Rettig MB; Berlin A; Tward JD; Davis BJ; Reiter RE; Steinberg ML; Elashoff D; Horwitz EM; Tendulkar RD; Tilki D
JAMA Netw Open; 2021 Jul; 4(7):e2115312. PubMed ID: 34196715
[TBL] [Abstract] [Full Text] [Related]
14. Efficacy of propiverine hydrochloride for urinary incontinence after robot-assisted or laparoscopic radical prostatectomy.
Ohba K; Miyata Y; Mukae Y; Mitsunari K; Matsuo T; Sakai H
Can J Urol; 2021 Jun; 28(3):10706-10712. PubMed ID: 34129467
[TBL] [Abstract] [Full Text] [Related]
15. Out-of-Pocket Costs and Perceived Financial Burden Associated with prostate cancer treatment in a Quebec Remote Area: A Cross-Sectional Study.
El-Haouly A; Lacasse A; El-Rami H; Liandier F; Dragomir A
Curr Oncol; 2020 Nov; 28(1):26-39. PubMed ID: 33704114
[No Abstract] [Full Text] [Related]
16. Downregulation of CDCA5 Can Inhibit Cell Proliferation, Migration, and Invasion, and Induce Apoptosis of prostate cancer Cells.
Chong Y; Xue L
Crit Rev Eukaryot Gene Expr; 2021; 31(1):29-40. PubMed ID: 33639053
[TBL] [Abstract] [Full Text] [Related]
17. TP53 alterations of hormone-naïve prostate cancer in the Chinese population.
Liu Z; Guo H; Zhu Y; Xia Y; Cui J; Shi K; Fan Y; Shi B; Chen S
Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):482-491. PubMed ID: 33214693
[TBL] [Abstract] [Full Text] [Related]
18.
Adams Q; Hopfensperger KM; Kim Y; Wu X; Flynn RT
Med Phys; 2020 Dec; 47(12):6430-6439. PubMed ID: 33051866
[TBL] [Abstract] [Full Text] [Related]
19. Identification of key genes and pathways in castrate-resistant prostate cancer by integrated bioinformatics analysis.
Wu YP; Ke ZB; Lin F; Wen YA; Chen S; Li XD; Chen SH; Sun XL; Huang JB; Zheng QS; Xue XY; Wei Y; Xu N
Pathol Res Pract; 2020 Oct; 216(10):153109. PubMed ID: 32853947
[TBL] [Abstract] [Full Text] [Related]
20. Risk stratification for prostate cancer management: value of the Cambridge Prognostic Group classification for assessing treatment allocation.
Parry MG; Cowling TE; Sujenthiran A; Nossiter J; Berry B; Cathcart P; Aggarwal A; Payne H; van der Meulen J; Clarke NW; Gnanapragasam VJ
BMC Med; 2020 May; 18(1):114. PubMed ID: 32460859
[TBL] [Abstract] [Full Text] [Related]
[Next]
